Amgen reported solid first-quarter growth driven by strong performance of new products like Repatha and Prolia, coupled with optimistic guidance for 2018. Management's positive tone on pipeline advancements and strategic expansions, along with improved non-GAAP earnings, suggests investor confidence. These factors are likely to bolster the stock in the short term.

[1]